MIRA Pharmaceuticals, Inc. (MIRA)
- Previous Close
0.9050 - Open
0.9171 - Bid --
- Ask --
- Day's Range
0.8500 - 0.9171 - 52 Week Range
0.7600 - 6.9500 - Volume
12,228 - Avg. Volume
672,868 - Market Cap (intraday)
12.709M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.50
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
mirapharmaceuticals.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MIRA
Performance Overview: MIRA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MIRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MIRA
Valuation Measures
Market Cap
12.71M
Enterprise Value
8.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.91
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.95
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-184.05%
Return on Equity (ttm)
-634.30%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-11.98M
Diluted EPS (ttm)
-0.6400
Balance Sheet and Cash Flow
Total Cash (mrq)
4.6M
Total Debt/Equity (mrq)
0.12%
Levered Free Cash Flow (ttm)
-4.73M